Compugen Ltd. released a corporate presentation outlining its immuno-oncology pipeline centered on AI and machine learning-enabled target discovery. The company highlights two fully owned clinical programs, COM701 (an Fc-reduced anti-PVRIG antibody) and COM902 (an Fc-reduced anti-TIGIT antibody), as well as partnered programs including AstraZeneca’s rilvegostomig, a PD-1/TIGIT bispecific antibody with the TIGIT component derived from COM902. The presentation also notes GS-0321 (previously COM503), an anti-IL-18 binding protein antibody licensed to Gilead, with Compugen responsible for preclinical work and the initial Phase 1 trial. The presentation provides pipeline and trial updates, including MAIA-ovarian evaluating COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer, with a projected randomized interim analysis in Q1 2027, and ongoing Phase 1 development of GS-0321 in solid tumors. It also reports a cash balance of $145.6 million as of December 31, 2025, and an expected cash runway into 2029. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.